cholecalciferol

Overview

Cholecalciferol, also known as vitamin D3, is a biologically active precursor of the vitamin D endocrine system and an important therapeutic and nutritional compound. It plays a central role in calcium-phosphorus homeostasis, supports bone mineralization, and contributes to immune regulation. In biomedical and pharmaceutical contexts, cholecalciferol is valued both as a supplement and as a formulation target because its clinical utility is constrained by poor aqueous solubility and limited oral bioavailability.

As a lipophilic molecule, cholecalciferol is often studied in delivery systems designed to improve absorption, stability, and tissue retention. Recent research has therefore focused on nanocarriers, emulsions, and other formulation strategies to enhance its performance, particularly for oral administration and co-delivery with other bioactive compounds such as riboflavin, vitamin K2, or polyphenol-based components.

Focus of Latest Publications

Recent publications on cholecalciferol have focused largely on improving its delivery and bioavailability, reflecting the compound’s poor aqueous solubility and limited oral absorption. Several studies developed nanoformulations to protect cholecalciferol during processing and storage, including nanoliposomal systems, Pickering emulsions, and other encapsulation platforms. A quality-by-design approach to nanoliposomal vitamin D3 identified process parameters that supported robust vesicle formation, efficient encapsulation, and stable vitamin retention under accelerated and real-time conditions. In a separate co-delivery system, egg white peptide/konjac glucomannan-stabilized high internal phase Pickering emulsions were used to carry vitamin D3 together with riboflavin, improving vitamin D3 bioaccessibility during simulated gastrointestinal digestion while maintaining long-term emulsion stability.

A more targeted oral delivery strategy used gallic acid-coated β-cyclodextrin/vitamin D3 nanovehicles to enhance intestinal adhesion and regional retention. In this study, cholecalciferol was first complexed with β-cyclodextrin to improve solubility and physicochemical stability, then coated with gallic acid to create a core-shell nanoparticle. The resulting formulation showed sustained release, high encapsulation efficiency, and increased cellular uptake in MDCK cells. Pharmacokinetic and tissue distribution analyses indicated markedly improved oral absorption compared with free cholecalciferol, with higher bioavailability in plasma, the small intestine, adipose tissue, and the stomach, along with prolonged retention in intestinal regions and associated adipose depots.

Other recent work examined nano-encapsulated vitamin D3 in biological and nutritional settings. In breeding pigeons, supplementation with nano-encapsulated VD3 in drinking water improved reproductive performance and egg quality at a moderate dose, with increases in egg mass, fertilization rate, luteinizing hormone, estradiol, testosterone, and antioxidant enzyme activity, alongside lower malondialdehyde levels. The highest dose further improved eggshell thickness and strength but did not add reproductive benefit and slightly reduced squab weight gain, suggesting a dose-dependent response. In a cancer-oriented study, vitamin D3-loaded keratin nanoparticles were evaluated in MCF-7 breast cancer cells and showed stronger anti-proliferative effects than vitamin D2-loaded nanoparticles, with the vitamin D3 formulation linked to downregulation of MCM-7 protein expression.

Cholecalciferol also appeared in a metabolomics-based study of Parkinson’s disease, where vitamin D3 was among the predicted consensus metabolite biomarkers associated with heterogeneous secretion patterns across patient clusters. This work did not test cholecalciferol as a therapy directly, but it highlighted its potential relevance to disease metabolism and patient stratification. Collectively, these publications emphasize cholecalciferol as a formulation-sensitive therapeutic agent whose recent research has centered on nanocarrier design, controlled release, improved bioavailability, and context-specific biological effects.

Key Publications

• May Gallic acid-driven core-shell nanovehicles enable intestinal adhesion and adipose retention for enhanced oral bioavailability of cholecalciferol. (Drug delivery, 2026, PMID 42108626): "Cholecalciferol (VDC), a vital form of vitamin D, is essential for maintaining calcium-phosphorus balance, promoting bone health, and regulating the immune system; however, its therapeutic potential is limited by low oral bioavailability and poor aqueous solubility."
• Jun Vitamin D3 and K2-loaded keratin nanoparticles inhibit breast cancer cell growth via MCM-7 downregulation and ROS induction. (International journal of biological macromolecules, 2026, PMID 42092663): "The present study highlights the anticancer potential of vitamins D2, D3, and K2-loaded keratin nanoparticles, exploring a novel approach to cancer treatment."
• Apr Nano-encapsulated vitamin D3 supplementation effects on reproductive performance, egg quality, and blood indexes in breeding pigeons. (Poultry science, 2026, PMID 42056822): "This study aimed to evaluate the effects of nano-encapsulated VD3 supplementation in drinking water on reproductive performance, egg quality, endocrine profiles, and antioxidant capacity of breeding White King pigeons."
• Apr Personalized metabolite biomarker predictions reveal heterogeneous characteristics of Parkinson's disease. (NPJ Parkinson's disease, 2026, PMID 42014729): "Consensus biomarkers included both well-known markers, such as dopamine and eumelanin, and additional metabolites, like salsolinol, vitamin D3, and retinal, with potential roles in PD mechanism and symptoms."
• May Process-guided design of nanoliposomal vitamin D3: formulation, stability and quality by design mapping. (International journal of pharmaceutics, 2026, PMID 41916513): "...able to protect and deliver vitamin D3 while maintaining technological simplicity and high tolerability."
• May Fabrication of egg white peptides/konjac glucomannan co-assembly stabilized high internal phase Pickering emulsions: Application for co-delivery of vitamin D3 and riboflavin. (Carbohydrate polymers, 2026, PMID 41831985): "...for the co-delivery of vitamin D3 and riboflavin sodium phosphate (RP) suffer from poor stability and low bioavailability; nevertheless, high internal phase Pickering emulsions (HIPPEs) feature a tunable microstructure that allows for effective compartmentalization of multiple components."